Feedback from those survivor sessions was also meant to help develop recommendations to improve the university's handling of sexual assault and formulate a comprehensive plan. Late in 2019, Stanley announced two new institutional planning initiatives, one focused on issues of diversity, equity, and inclusion and the other a comprehensive university strategic planning process. He also launched an initiative in late 2019 to investigate development of a campus multicultural center. Stanley restructured administration of the university's medical, osteopathic and nursing colleges and its clinical services in October 2019 to improve oversight and alignment of health care, education, and research activities. The university broke ground Nov. 18, 2019 on a $19.5 million, gift-funded medical innovation facility next to MSU's $88.1 million Grand Rapids Research Center and close to its College of Human Medicine in downtown Grand Rapids. Stanley announced his resignation from Michigan State on October 13, 2022, stating that he no longer had confidence in the university's Board of Trustees. Some members of the Board had been pressing him to retire, based on their criticism of his handling of the case of a dean in the Broad College of Business, who had been made to leave after allegations of sexual misconduct. Stanley's resignation was scheduled to take effect on January 11, 2023, but his last day November 4, 2022. He was the third MSU president in a row to tender his resignation since January 2018. Biomedical research Stanley was a biomedical researcher. His research interest in immunity from infections led him to publish several articles about the characterization of key proteins and pathways involved in amebic, bacterial and viral infections, blood-borne pathogen risks in hemophilia therapy, and the identification of new strain- specific clones. Better defense against infection was a key focus of his research. In 2008, he worked to create the Midwest Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research, with a $37 million grant from the National Institutes of Health. The center was established with goals of improving biodefense, in reaction to the post-September 11 bioterrorism threat and anthrax attacks. He has also served on the National Science Advisory Board for Biosecurity, the NIH Blue Ribbon Panel on the New England Infectious Diseases Research Laboratory, the NIH National Advisory Allergy & Infectious Diseases Council and committees led by the United States Department of Commerce. Stanley is also the recipient of awards, including the Burroughs Wellcome Scholar